KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Operating Leases (2019 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Operating Leases for 7 consecutive years, with $145.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases fell 15.83% to $145.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $145.7 million, a 15.83% decrease, with the full-year FY2025 number at $145.7 million, down 15.83% from a year prior.
  • Operating Leases was $145.7 million for Q4 2025 at Bio-Rad Laboratories, down from $155.8 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $212.9 million in Q3 2021 to a low of $145.7 million in Q4 2025.
  • A 5-year average of $176.4 million and a median of $168.3 million in 2021 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: decreased 28.81% in 2023, then surged 35.19% in 2025.
  • Bio-Rad Laboratories' Operating Leases stood at $212.3 million in 2021, then fell by 27.65% to $153.6 million in 2022, then rose by 7.75% to $165.5 million in 2023, then rose by 4.59% to $173.1 million in 2024, then dropped by 15.83% to $145.7 million in 2025.
  • Per Business Quant, the three most recent readings for BIO's Operating Leases are $145.7 million (Q4 2025), $155.8 million (Q3 2025), and $204.1 million (Q2 2025).